Honasa Consumer Acquires Majority Stake in Fluence Pharma to Expand into Nutraceuticals

Honasa Consumer Acquires Majority Stake in Fluence Pharma to Expand into Nutraceuticals​

Honasa Consumer Ltd has approved the acquisition of a majority stake in Fluence Pharma Private Limited, a science-led nutraceuticals company specializing in condition-specific over-the-counter (OTC) supplements. The move is complemented by the Board's approval to incorporate a wholly owned subsidiary, Honasa Health Private Limited, dedicated to consumer-facing B2C operations within the nutraceutical sector.

The acquisition targets Fluence Pharma, which offers products under the brands 'Hair Fact, Skin Fact and Pro Fact'. Honasa Consumer will acquire a 58% equity stake through a secondary purchase transaction at an enterprise value of approximately $\text{₹} 135 \text{ Crores}$, subject to closing adjustments.

The company intends to complete the initial acquisition within 8 weeks. The remaining 42% equity stake in Fluence Pharma will be acquired over two tranches spanning the next 5 to 7 years, based on a pre-aligned valuation structure of EV / FY26 EBITDA.

Strategic Expansion and Company Details​

The acquisition marks Honasa Consumer's entry into the rapidly growing nutraceutical market. This strategy aims to strengthen the company's portfolio with a differentiated, patented brand in the sector. The new entity, Honasa Health Private Limited, is slated to undertake all consumer-to-business (B2C) operations of the nutraceutical business, utilizing Fluence Pharma's patented Cyclical Nutrition Therapy as its core intellectual property.

Fluence Pharma has established itself through a strong doctor network and evidence based performance. The company boasts over 3,000 dermatologists who trust and prescribe Fluence products, which have demonstrated in clinic effectiveness for more than 10 years. Hair focused solutions are currently the primary revenue driver, contributing over 70% of the business.

Transaction Details and Financial Overview​

The transaction details reflect a strategic move into a high growth category, as global demand increases for inside out health solutions, with the nutraceutical market in India projected to grow at an 11% CAGR and reaching a size of $\text{INR } 16 \text{K Cr+}$ in FY25.

Key financial details regarding the acquisition and Fluence Pharma are summarized below:


The financial history of Fluence Pharma is as follows:


In addition to the acquisition, Honasa Consumer is also moving forward with the incorporation of Honasa Health Private Limited in India, which will be established as a wholly owned subsidiary and holds 100% equity stake, aiming to scale the nutraceuticals franchise into $\text{INR } 500 \text{ Cr}$ within this segment.

HONASA Stock Price Movement​

Today, Honasa Consumer Limited shares edged higher to close at ₹419.90, gaining 1.00% in trading. The stock saw a volume of 765,764 shares during the session.